
Sunesis Pharmaceuticals, Inc. Risk Report
Generated on July 16, 2025
1
Risks
Summary
π‘οΈ Financial & Liquidity
Sunesis Pharmaceuticals has faced financial challenges, especially evident in the past performance of its stock and associated entities. Viracta's stock plunged to a 52-week low of $0.08, reflecting significant financial strain. Strategic mergers and financial decisions highlight their ongoing efforts to stabilize and grow.
- Viracta Therapeutics, post-merger with Sunesis, experienced a stock value plunge to $0.08 on π February 3, 2025.
- The merger with Viracta Therapeutics was finalized, along with a $65 million private placement π on February 25, 2021.
βοΈ Legal & Regulatory
No significant legal or regulatory issues have been reported for Sunesis Pharmaceuticals, indicating compliance with industry standards.
π₯ Labor & Workforce
No notable labor or workforce-related events were found in the data provided for Sunesis Pharmaceuticals.
ποΈ Operational & Business Continuity
Sunesis Pharmaceuticals experienced operational challenges impacting business continuity. The cessation of vosaroxin in Europe marked a critical operational decision affecting their European market strategy.
- Sunesis Pharmaceuticals terminated its European leukemia drug, vosaroxin, operations π on May 2, 2017.
π Innovation & R&D
Sunesis Pharmaceuticals maintains a focus on innovation and R&D, as seen in their external collaborations and developments. This remains a key driver for future opportunities in the biotech sector.
- The company received FDA fast track designation for vosaroxin in AML, marking a significant milestone π on February 23, 2011.
- Clinical updates were announced on the vecabrutinib program, representing ongoing R&D efforts π on June 23, 2020.
π Awards & Recognition
No awards or recognition were noted in the current data for Sunesis Pharmaceuticals.
News & Media
Stay informed with real-time news signals across financial, legal, and operational domains.